Physician profile
Henry C Costa
NPI 1134125651
$8,853.81
in general payments reported to CMS, 2019-2025
13 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $469 · 2021: $2,076 · 2022: $1,188 · 2023: $695 · 2024: $1,810 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,053.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,434.55 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $2,188.22 | 2019-2025 | Biktarvy, Descovy |
| Janssen Products, LP | $745.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $669.08 | 2020-2025 | Pifeltro, Delstrigo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $426.75 | 2021-2023 | Breztri |
| Janssen Biotech, INC. | $404.85 | 2020-2023 | Symtuza |
| Janssen Scientific Affairs, LLC | $340.35 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $178.70 | 2019-2021 | |
| Allergan, INC. | $178.12 | 2019-2020 | |
| Emd Serono, INC. | $145.87 | 2024-2025 | |
| Glaxosmithkline, LLC. | $74.50 | 2021 | |
| Napo Pharmaceuticals INC | $43.46 | 2024-2025 | Mytesi |
| Abbott Laboratories | $23.82 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.